A Monoiodotyrosine Challenge Test in a Parkinson's Disease Model

A R Kim; E N Pavlova; V E Blokhin; V V Bogdanov; M V Ugrumov

doi:10.32607/actanaturae.11399

A Monoiodotyrosine Challenge Test in a Parkinson's Disease Model

Acta Naturae. 2021 Jul-Sep;13(3):106-109. doi: 10.32607/actanaturae.11399.

Authors

A R Kim¹, E N Pavlova¹, V E Blokhin¹, V V Bogdanov¹, M V Ugrumov¹

Affiliation

¹ Koltzov Institute of Developmental Biology of Russian Academy of Sciences, Moscow,119334 Russia.

Abstract

Early (preclinical) diagnosis of Parkinson's disease (PD) is a major challenge in modern neuroscience. The objective of this study was to experimentally evaluate a diagnostic challenge test with monoiodotyrosine (MIT), an endogenous inhibitor of tyrosine hydroxylase. Striatal dopamine was shown to decrease by 34% 2 h after subcutaneous injection of 100 mg/kg MIT to intact mice, with the effect not being amplified by a further increase in the MIT dose. The selected MIT dose caused motor impairment in a neurotoxic mouse model of preclinical PD, but not in the controls. This was because MIT reduced striatal dopamine to the threshold of motor symptoms manifestation only in PD mice. Therefore, using the experimental mouse model of preclinical PD, we have shown that a MIT challenge test may be used to detect latent nigrostriatal dysfunction.

Keywords: MPTP; Parkinson’s disease; challenge test; early diagnosis; monoiodotyrosine.